This study utilized RCC samples from large-scale, global, multicenter sequencing cohorts and first proved that genomic alteration of MTAP/CDKN2A significantly correlates with sarcomatoid differentiation in RCC and predicts aggressive progression, poor prognosis, primary resistance to targeted therapy, and potential favorable responses to immune checkpoint blockade. This evidence concerns the gene CDKN2A and renal cell carcinoma.